Metabolic and Functional Study of γδ T Cells in Critically Ill Patients
Subset-specific Metabolic Adaptation and Functional Remodeling of Gamma Delta T (γδ T) Cells in Critically Ill ICU Patients: A Single-center, Prospective, Observational Cohort Study.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Outside of the US
-
Wuhan, Outside of the US, China, 430022
- Recruiting
- Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Jiancheng Zhang, Dr.
- Phone Number: 13554105815
- Email: zhjcheng1@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Healthy Control Group (NHC):
- Age ≥ 18 years.
- No acute or chronic major diseases.
- Provide written informed consent.
Non-septic Critical Illness Group (CI-NS):
- Age ≥ 18 years.
- Admitted to the ICU and meeting the definition of critical illness.
- Excluded from sepsis according to the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points).
- Written informed consent provided by the participant or legally authorized representative.
Septic Critical Illness Group (CI-Sep):
- Age ≥ 18 years.
- Admitted to the ICU and meeting the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points).
- Written informed consent provided by the participant or legally authorized representative.
Exclusion Criteria:
- Age < 18 years.
- Known immunodeficiency, HIV infection, active hematologic malignancy, or history of hematopoietic stem cell or solid organ transplantation within the past 3 months.
- Receipt of T-cell-targeted immunosuppressive therapy (e.g., antithymocyte globulin, calcineurin inhibitors, mycophenolate mofetil, methotrexate, or high-dose corticosteroids >1 mg/kg/day prednisone equivalent) before ICU admission or within 24 hours after ICU admission.
- Use of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1/CTLA-4 antibodies) within the past 6 weeks.
- Expected ICU stay < 24 hours or imminent risk of death (moribund state).
- Pregnancy or breastfeeding.
- Active major bleeding.
- Inability to obtain informed consent.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Healthy Controls (NHCs)
Healthy volunteers without acute or chronic major diseases, aged ≥18 years, who have provided written informed consent.
Participants undergo a single blood draw and rectal swab collection.
|
|
Critically Ill Non-Septic Patients (CI-NS)
Patients admitted to the ICU meeting the criteria for critical illness but without sepsis, as determined by the Sepsis-3 criteria (infection with ΔSOFA ≥ 2 points excluded).
Participants are aged ≥18 years, with informed consent obtained from the patient or legally authorized representative.
Blood and rectal swab samples are collected at three time points: within 24 hours of ICU admission (D0), Day 2 (D2), and Day 7 (D7).
Clinical follow-up extends to 90 days.
|
|
Critically Ill Septic Patients (CI-Sep)
Patients admitted to the ICU meeting the Sepsis-3 criteria (infection with ΔSOFA ≥ 2 points).
Participants are aged ≥18 years, with informed consent obtained from the patient or legally authorized representative.
Blood and rectal swab samples are collected at three time points: within 24 hours of ICU admission (D0), Day 2 (D2), and Day 7 (D7).
Clinical follow-up extends to 90 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the Proportion of Cytotoxic γδT Cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) Among Total γδT Cells
Time Frame: Day 2 post-ICU admission
|
Flow cytometric quantification of the frequency of Cytotoxic γδT cells, defined as TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺ cells, as a percentage of total γδT cells (TCRγδ⁺) in peripheral blood.
This subset represents the cytotoxic effector population critical for early anti-infection defense.
|
Day 2 post-ICU admission
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in COX6C Expression in Cytotoxic γδT Cells
Time Frame: Day 2 post-ICU admission
|
Measurement of COX6C (mitochondrial respiratory chain complex IV subunit) expression levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at the mRNA level (by single-cell RNA sequencing) and protein level (by flow cytometry).
|
Day 2 post-ICU admission
|
|
Change in Cytotoxic Molecule Expression in Cytotoxic γδT Cells
Time Frame: Day 2 post-ICU admission
|
Flow cytometric quantification of the mean fluorescence intensity (MFI) of cytotoxic effector molecules including Granzyme B (GZMB), Perforin (PRF1), and Granulysin (GNLY) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Mitochondrial Mass in Cytotoxic γδT Cell
Time Frame: Day 2 post-ICU admission
|
Flow cytometric quantification of mitochondrial mass using MitoTracker Green FM staining in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Mitochondrial Membrane Potential (TMRE) in Cytotoxic γδT Cells
Time Frame: Day 2 post-ICU admission
|
Flow cytometric quantification of mitochondrial membrane potential using tetramethylrhodamine ethyl ester (TMRE) staining in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Mitochondrial Membrane Potential (JC-1) in Cytotoxic γδT Cells
Time Frame: Day 2 post-ICU admission
|
Flow cytometric quantification of mitochondrial membrane potential using JC-1 dye (red/green fluorescence ratio) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Oxygen Consumption Rate (OCR) in Cytotoxic γδT Cells
Time Frame: Day 2 post-ICU admission
|
Measurement of basal oxygen consumption rate reflecting oxidative phosphorylation (OXPHOS) capacity in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Extracellular Acidification Rate (ECAR) in Cytotoxic γδT Cells
Time Frame: Day 2 post-ICU admission
|
Measurement of basal extracellular acidification rate reflecting glycolytic metabolic activity in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
|
Day 2 post-ICU admission
|
|
Change in Glycolytic Capacity of Cytotoxic γδT Cells at Serial Time Points
Time Frame: Day 0, Day 2, and Day 7 post-ICU admission
|
Longitudinal flow cytometric puromycin-incorporation assay (SCENITH method) to measure glycolytic capacity in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at Day 0, Day 2, and Day 7 post-ICU admission, to track the temporal evolution of metabolic flexibility and stress-adaptive glycolytic reprogramming during the course of critical illness.
|
Day 0, Day 2, and Day 7 post-ICU admission
|
|
Change in Mitochondrial ROS Levels in Cytotoxic γδT Cells at Serial Time Points
Time Frame: Day 0, Day 2, and Day 7 post-ICU admission
|
Longitudinal flow cytometric quantification of mitochondrial reactive oxygen species (mitochondrial ROS) levels using MitoSOX Green staining in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at Day 0, Day 2, and Day 7 post-ICU admission, reflecting oxidative stress dynamics.
|
Day 0, Day 2, and Day 7 post-ICU admission
|
|
Change in Cytotoxic γδT Cell Migratory Function
Time Frame: Day 2 post-ICU admission
|
Assessment of Cytotoxic γδT cell (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) chemotactic and migratory capacity using Transwell migration assay.
|
Day 2 post-ICU admission
|
|
Change in Total γδT Cell Proportion at Serial Time Points
Time Frame: Day 0, Day 2, and Day 7 post-ICU admission
|
Longitudinal flow cytometric quantification of the frequency of total γδT cells (TCRγδ⁺) as a percentage of total live CD3⁺ T cells in peripheral blood at Day 0, Day 2, and Day 7 post-ICU admission.
|
Day 0, Day 2, and Day 7 post-ICU admission
|
|
Change in Cytotoxic γδT Cell Proportion at Serial Time Points
Time Frame: Day 0, Day 2, and Day 7 post-ICU admission
|
Longitudinal flow cytometric quantification of the frequency of Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) as a percentage of total γδT cells at Day 0, Day 2, and Day 7 post-ICU admission, to track the temporal evolution of this cell subset.
|
Day 0, Day 2, and Day 7 post-ICU admission
|
|
Change in COX6C Expression in Cytotoxic γδT Cells at Serial Time Points
Time Frame: Day 0, Day 2, and Day 7 post-ICU admission
|
Longitudinal measurement of COX6C expression levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at Day 0, Day 2, and Day 7 post-ICU admission, to assess the temporal dynamics of mitochondrial metabolic gene expression.
|
Day 0, Day 2, and Day 7 post-ICU admission
|
|
Correlation Between Cytotoxic γδT Cell Glycolytic Capacity and APACHE II Score
Time Frame: Day 2 post-ICU admission
|
Spearman rank correlation analysis between glycolytic capacity (measured by puromycin incorporation assay at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with APACHE II (Acute Physiology and Chronic Health Evaluation II) score measured within the first 48 hours of ICU admission.
|
Day 2 post-ICU admission
|
|
Correlation Between Cytotoxic γδT Cell Glycolytic Capacity and SOFA Score
Time Frame: Day 2 post-ICU admission
|
Spearman rank correlation analysis between glycolytic capacity (measured by puromycin incorporation assay at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with SOFA (Sequential Organ Failure Assessment) score measured within the first 48 hours of ICU admission.
|
Day 2 post-ICU admission
|
|
Correlation Between Cytotoxic γδT Cell Metabolic Parameters and vasopressor dose
Time Frame: Day 2 post-ICU admission
|
Correlation analysis between COX6C expression, glycolytic capacity, and mitochondrial ROS levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with vasopressor dose (reported as norepinephrine equivalent dose, NEE).
|
Day 2 post-ICU admission
|
|
Correlation Between Cytotoxic γδT Cell Metabolic Parameters and plasma lactate levels
Time Frame: Day 2 post-ICU admission
|
Correlation analysis between COX6C expression, glycolytic capacity, and mitochondrial ROS levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with plasma lactate levels.
|
Day 2 post-ICU admission
|
|
Association Between Cytotoxic γδT Cell Glycolytic Capacity and 28-day all-cause mortality
Time Frame: Up to 90 days post-discharge
|
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and 28-day all-cause mortality.
Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
|
Up to 90 days post-discharge
|
|
Association Between Cytotoxic γδT Cell Glycolytic Capacity and 90-day all-cause mortality
Time Frame: Up to 90 days post-discharge
|
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and 90-day all-cause mortality.
Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
|
Up to 90 days post-discharge
|
|
Association Between Cytotoxic γδT Cell Glycolytic Capacity and in-hospital mortality
Time Frame: Up to 90 days post-discharge
|
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and in-hospital mortality.
Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
|
Up to 90 days post-discharge
|
|
Association Between Cytotoxic γδT Cell Glycolytic Capacity and ICU mortality
Time Frame: Up to 90 days post-discharge
|
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and ICU mortality.
Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
|
Up to 90 days post-discharge
|
|
Association Between Cytotoxic γδT Cell Glycolytic Capacity and hospital length of stay
Time Frame: Up to 90 days post-discharge
|
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and hospital length of stay (days).
Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
|
Up to 90 days post-discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- zjc202612
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.